Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept, Inc.'s Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, today announced that findings demonstrating the ability to reliably detect actionable genetic alterations used in the diagnosis, monitoring and treatment of patients with lung cancer using its blood based biopsy, instead of surgical biopsy, will be presented Friday, November 6th, at the Association for Molecular Pathology Annual (AMP) Meeting in Austin, Texas.

Help employers find you! Check out all the jobs and post your resume.